Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 13/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | FHIT | P49789 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325253 | 0.84 | NT5E (0.48) | POLBSTING1P2RY2P2RY4P2RY6 | |
| SCHEMBL20326933 | 0.83 | POLB (0.52) | POLBSTING1P2RY2P2RY4P2RY6 | |
| SCHEMBL20327610 | 0.83 | NT5E (0.48) | STING1FHITNT5E | |
| SCHEMBL20326983 | 0.82 | STING1 (0.40) | POLBSTING1 | |
| SCHEMBL20324745 | 0.82 | STING1 (0.39) | POLBSTING1 | |
| SCHEMBL20324552 | 0.82 | STING1 (0.39) | POLBSTING1 | |
| SCHEMBL20326953 | 0.81 | STING1 (0.49) | POLBSTING1NT5E | |
| SCHEMBL20325358 | 0.81 | STING1 (0.49) | POLBSTING1NT5E | |
| SCHEMBL21540039 | 0.80 | POLB (0.49) | POLBSTING1 | |
| SCHEMBL22434625 | 0.80 | POLB (0.62) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |